Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Longevity & Anti-Aging

MOTS-c

Cyclic AMP-dependent transcription factor ATF-1

Evidence: Limited human data Disclaimer: Elevated Not FDA-approved
Elevated-disclaimer compound. Not approved by the FDA. Evidence is limited to animal models or small human studies. Safety in humans has not been established.

Mechanism & research context

Studied for metabolic regulation, insulin sensitivity, and exercise adaptation in animal models and early human pharmacokinetic studies.

Origin: Mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

17 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

8 records
  • Live search Live search

    Live ClinicalTrials.gov search: MOTS-c

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT03878706 RECRUITING

    The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk

    Condition: Diabetes Mellitus, Type 2

    Sponsor: University of Athens

    Open on ClinicalTrials.gov ↗
  • NCT04013568 NA COMPLETED

    A Pilot Study: The Effect of Longitudinal Exercise Programming in Breast Cancer Patients

    Condition: Breast Cancer

    Sponsor: University of Hawaii

    Open on ClinicalTrials.gov ↗
  • NCT04027712 UNKNOWN

    High On-treatment Platelet Reactivity, Increased B-amyloid and Downregulation of MOTS-c Predict Mortality in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus: a 2-year Follow up Study

    Condition: Diabetes; Clopidogrel Resistance; Amyloid; Insulin Resistance

    Sponsor: University of Athens

    Open on ClinicalTrials.gov ↗
  • NCT06133946 ACTIVE_NOT_RECRUITING

    Cohort of Universal Newborn Deafness-gene Screening in Nantong City, China

    Condition: Hearing Loss

    Sponsor: Affiliated Hospital of Nantong University

    Open on ClinicalTrials.gov ↗
  • NCT06500975 NA RECRUITING

    Long Term Outcomes After Vestibular Implantation

    Condition: Bilateral Vestibular Hypofunction; Bilateral Vestibular Deficiency; Bilateral Vestibulopathy; Gentamicin Ototoxicity; Aminoglycoside Toxicity; Vestibular Diseases; Sensation Disorders; Labyrinth Diseases; Other Disorders of Vestibular Function

    Sponsor: Johns Hopkins University

    Open on ClinicalTrials.gov ↗
  • NCT07438002 NA RECRUITING

    Effect of Exercise in Patients With Chronic Kidney Disease: TONE Trial

    Condition: Chronic Kidney Disease

    Sponsor: Casa di Cura Dott. Pederzoli

    Open on ClinicalTrials.gov ↗
  • NCT07505745 PHASE2 RECRUITING

    A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity

    Condition: Prediabetes; Insulin Resistance; Overweight/Obesity

    Sponsor: Hudson Biotech

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for MOTS-c yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of MOTS-c, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for MOTS-c. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.